NCT03829384View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 22, 2019

Primary Completion Date

June 7, 2021

Study Completion Date

June 7, 2021

Conditions
Prevention of Chikungunya Virus Infection
Interventions
BIOLOGICAL

mRNA-1944

mRNA encoding Chikungunya antibody

OTHER

Placebo

Saline

Trial Locations (1)

78744

PPD Phase 1 Clinical Research Unit, Austin

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY

NCT03829384 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults | Biotech Hunter | Biotech Hunter